Sort   by:  
 Page size 
GenomicsTranscriptome analyses of bEV treated HEK293T cells
Transcriptome analyses of bEV treated HEK293T cells
PRJNA1128539 | ENA
TranscriptomicsTranscriptome analyses of bEV treated HEK293T cells
To get insight of molecular effects of bEV on HEK293T cells, we investigated transcriptomic response in bEV treated HEK293T cells We identified differentially expressed genes (DEGs) fold change cutoff = 1.5 in the bEV treated HEK293T cells These findings suggest that bEV would be putative ingredient...
ORGANISM(S): Homo sapiens 
2025-07-12 | GSE270805 | GEO
GenomicsSymbiopectobacterium
BEV proteobacterium overview
PRJNA60281 | ENA
UnknownA randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
Not available
S-EPMC3173448 | biostudies-literature
GenomicsCandidatus Symbiopectobacterium sp. 'Berkeley'
BEV proteobacterium str. Berkeley genome sequencing
PRJNA60249 | ENA
UnknownBEV-IP: Perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis.
Not available
S-EPMC4682259 | biostudies-literature
Proteomicso Differential temporal release and lipoprotein loading in B. thetaiotaomicron bacterial extracellular vesicles
o Bacterial extracellular vesicles (BEVs) contribute to stress responses, quorum sensing, biofilm formation, and interspecies and interkingdom communication. However, the factors that regulate their release and heterogeneity are not well understood. We set out to investigate these factors in the com...
ORGANISM(S): Bacteroides thetaiotaomicron 
2024-01-22 | PXD043651 | Pride
O outer membrane vesicles  omv  bacterial extracellular vesicles  bev  bacteroides 
UnknownAT-11FINAL RESULTS FROM THE RANDOMIZED PHASE II TRIAL AVAREG (ML25739) WITH BEVACIZUMAB (BEV) OR FOTEMUSTINE (FTM) IN RECURRENT GBM
Not available
S-EPMC4217788 | biostudies-literature
UnknownApplication of Baculovirus Expression Vector system (BEV) for COVID-19 diagnostics and therapeutics: a review.
Not available
S-EPMC9259773 | biostudies-literature
ClinicalFolfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC
Bev improves the efficacy of first-line chemotherapy in unresectable mCRC. In the phase III TRIBE trial upfront FOLFOXIRI plus bev provided a significant advantage in terms of PFS and RR compared to FOLFIRI plus bev. A trend toward better OS was also evidenced. The second-line treatment was at inves...
2181974 | ecrin-mdr-crc
Sort   by:  
 Page size